Actinium Pharmaceuticals, Inc.
AMEX:ATNMBiotechnology
+$0.22 today
- Market cap
- $51.56M
- Beta
- 0.02
- P/E (TTM)
- 4.4
- EPS (TTM)
- $0.36
Volume 0.18M
Average 0.15M
ATNM EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Actinium Pharmaceuticals, Inc.AMEX: ATNM
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA turns positive
Q2 FY2026 EBITDA was $28.14M, compared with -$6.67M a year earlier. Trailing-twelve-month EBITDA was $12.18M.
Context
- EBITDA amounted to 36740.0% of revenue in FY2025.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of $10.33M (+131.2%) for the fiscal year ending Dec 2026, a step up from the +11.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $28.14M+630.8% QoQ
- Last fiscal yearDec 2025
- -$33.07M+11.7% YoY
- LTMJun 2026
- $12.18M+130.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +521.7% | -49.9% | -571.6 pp |
| 1 year | +11.7% | +131.2% | +119.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (33.07M) USD
- Year-over-year change
- +11.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (33.07M) | +11.7% |
| FY2024 | 2024-12-31 | (37.43M) | +22.1% |
| FY2023 | 2023-12-31 | (48.03M) | -48.6% |
| FY2022 | 2022-12-31 | (32.32M) | -33.3% |
| FY2021 | 2021-12-31 | (24.25M) | — |
EBITDA vs competitors
How ATNM compares with its peers on the latest reported figures
- ATNM's LTM Jun 2026 EBITDA of $12.18M is the highest of the 5 companies compared; the peer median is -$35.42M.
- Its year-over-year change of +130.3% is the highest of 5, against a peer median of +12.9%.
- EBITDA amounts to 34.7% of revenue for ATNM, versus a peer median of 55.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $12.18M | +130.3% | — | 34.7% | |
| LTM Mar 2026 | -$27.92M | +15.6% | — | — | |
| LTM Mar 2026 | -$29.91M | +44.7% | — | 55.9% | |
| LTM Mar 2026 | -$40.92M | -50.5% | — | — | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | -$57.92M | +10.2% | — | — |
| Peer median (excluding ATNM) | -$35.42M | +12.9% | — | 55.9% | |
Competitors are the stored peer set for ATNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.14M | 1.03M | 81K | 0 | 90K |
| Cost of Revenue | 524K | 0 | 0 | 811K | 0 |
| Gross Profit | 620K | 1.03M | 81K | (811K) | 90K |
| Gross Margin | 54.2% | 100.0% | 100.0% | — | 100.0% |
| Research & Development | 17.51M | 23.14M | 38.67M | 30.05M | 21.12M |
| Selling, General & Admin | 8.08M | 12M | 13.33M | 12.08M | 15.21M |
| Operating Expenses | 25.58M | 35.13M | 52M | 41.31M | 36.34M |
| Depreciation & Amortization | 524K | 699K | 790K | 811K | 821K |
| EBITDA | (24.25M) | (32.32M) | (48.03M) | (37.43M) | (33.07M) |
| EBITDA Margin | -2119.8% | -3137.7% | -59293.8% | — | -36740.0% |
| Operating Income | (24.96M) | (34.1M) | (51.92M) | (42.12M) | (36.25M) |
| Operating Margin | -2182.2% | -3311.1% | -64098.8% | — | -40274.4% |
| Interest Income | 190K | 1.09M | 3.1M | 3.88M | 2.36M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 190K | 1.09M | 3.1M | 3.88M | 2.36M |
| Income Before Tax | (24.77M) | (33.02M) | (48.82M) | (38.24M) | (33.89M) |
| Pre-Tax Margin | -2165.6% | -3205.5% | -60269.1% | — | -37652.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.77M) | (33.02M) | (48.82M) | (38.24M) | (33.89M) |
| Net Margin | -2165.6% | -3205.5% | -60269.1% | — | -37652.2% |
| EPS (Basic) | (1.20) | (1.37) | (1.83) | (1.27) | (1.09) |
| EPS (Diluted) | (1.20) | (1.37) | (1.83) | (1.27) | (1.09) |
| Weighted Avg Shares | 20.57M | 24.14M | 26.6M | 30.07M | 31.2M |
| Weighted Avg Shares (Diluted) | 20.57M | 24.14M | 26.6M | 30.07M | 31.2M |
Actinium Pharmaceuticals, Inc.
AMEX:ATNM
Intrinsic Alpha fair value
Locked
Current Price
$1.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.